

NCT ID	NCT04362839
Title	Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2020-04-27
Location	California, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy
Tags	MSS/ MMRp
NCT ID	NCT04110093
Title	Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Phase	Phase 1/Phase 2
Date Added	2019-10-01
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Regorafenib and PD-1 inhibitor
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06006923
Title	Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
Phase	Phase 2
Date Added	2023-08-23
Location	California, United States Florida, United States Illinois, United States Pennsylvania, United States Washington, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Pembrolizumab, Regorafenib, Keytruda, Stivarga
Tags	MSI-H/ MMRd
NCT ID	NCT06456515
Title	Regorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC
Phase	Not Applicable
Date Added	2024-06-13
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT03657641
Title	Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
Phase	Phase 1

Date Added	2018-09-05
Location	California, United States Florida, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Regorafenib, Keytruda, Stivarga
Tags	MSS/ MMRp
NCT ID	NCT04626635
Title	REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2020-11-12
Location	California, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States France Israel Netherlands Poland Spain Turkey
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	cemiplimab, REGN7075
Tags	MSS/ MMRp
NCT ID	NCT03388632
Title	Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
Phase	Phase 1
Date Added	2018-01-03
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05785325
Title	RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Phase	Phase 2
Date Added	2023-03-27
Location	China

Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	RC48-ADC plus Bevacizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05292417
Title	Radiotherapy in Combination With Sintilimab?GM-CSF and Fruquintinib in Patients With MSS mCRC
Phase	Phase 2
Date Added	2022-03-23
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Fruquintinib, GM-CSF, Sintilimab
Tags	MSS/ MMRp
NCT ID	NCT04050709
Title	QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Phase	Phase 1
Date Added	2019-08-08
Location	California, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	PD-L1 t-haNK
Tags	MSS/ MMRp